• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

安捷伦基于杂交捕获的靶向大规模平行测序所需的起始DNA最小量。

The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing.

作者信息

Chung Jongsuk, Son Dae-Soon, Jeon Hyo-Jeong, Kim Kyoung-Mee, Park Gahee, Ryu Gyu Ha, Park Woong-Yang, Park Donghyun

机构信息

Samsung Biomedical Research Institute, Samsung Advanced Institute of Technology, Samsung Electronics Co. Ltd., Seoul 06351, Korea.

Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.

出版信息

Sci Rep. 2016 May 25;6:26732. doi: 10.1038/srep26732.

DOI:10.1038/srep26732
PMID:27220682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4879621/
Abstract

Targeted capture massively parallel sequencing is increasingly being used in clinical settings, and as costs continue to decline, use of this technology may become routine in health care. However, a limited amount of tissue has often been a challenge in meeting quality requirements. To offer a practical guideline for the minimum amount of input DNA for targeted sequencing, we optimized and evaluated the performance of targeted sequencing depending on the input DNA amount. First, using various amounts of input DNA, we compared commercially available library construction kits and selected Agilent's SureSelect-XT and KAPA Biosystems' Hyper Prep kits as the kits most compatible with targeted deep sequencing using Agilent's SureSelect custom capture. Then, we optimized the adapter ligation conditions of the Hyper Prep kit to improve library construction efficiency and adapted multiplexed hybrid selection to reduce the cost of sequencing. In this study, we systematically evaluated the performance of the optimized protocol depending on the amount of input DNA, ranging from 6.25 to 200 ng, suggesting the minimal input DNA amounts based on coverage depths required for specific applications.

摘要

靶向捕获大规模平行测序在临床环境中的应用日益广泛,且随着成本持续下降,这项技术在医疗保健领域的使用可能会成为常规操作。然而,在满足质量要求方面,组织样本量有限常常是一项挑战。为了提供关于靶向测序所需最低输入DNA量的实用指南,我们根据输入DNA量对靶向测序的性能进行了优化和评估。首先,我们使用不同量的输入DNA,比较了市售的文库构建试剂盒,并选择了安捷伦的SureSelect-XT试剂盒和卡帕生物系统公司的Hyper Prep试剂盒,作为与使用安捷伦SureSelect定制捕获进行靶向深度测序最兼容的试剂盒。然后,我们优化了Hyper Prep试剂盒的接头连接条件,以提高文库构建效率,并采用多重杂交选择来降低测序成本。在本研究中,我们系统地评估了根据输入DNA量(范围为6.25至200 ng)优化后的方案的性能,根据特定应用所需的覆盖深度提出了最低输入DNA量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/42b82e9b48d5/srep26732-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/e1b48597c4e8/srep26732-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/de0eacbb029f/srep26732-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/0333278b8b93/srep26732-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/42b82e9b48d5/srep26732-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/e1b48597c4e8/srep26732-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/de0eacbb029f/srep26732-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/0333278b8b93/srep26732-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b5f/4879621/42b82e9b48d5/srep26732-f4.jpg

相似文献

1
The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing.安捷伦基于杂交捕获的靶向大规模平行测序所需的起始DNA最小量。
Sci Rep. 2016 May 25;6:26732. doi: 10.1038/srep26732.
2
Performance evaluation of commercial library construction kits for PCR-based targeted sequencing using a unique molecular identifier.基于独特分子标识符的 PCR 靶向测序商业文库构建试剂盒的性能评估。
BMC Genomics. 2019 Mar 14;20(1):216. doi: 10.1186/s12864-019-5583-7.
3
Evaluation of the Illumina(®) Beta Version ForenSeq™ DNA Signature Prep Kit for use in genetic profiling.用于基因分析的Illumina(®) Beta版本ForenSeq™ DNA签名制备试剂盒的评估。
Forensic Sci Int Genet. 2016 Jan;20:20-29. doi: 10.1016/j.fsigen.2015.09.009. Epub 2015 Sep 21.
4
Performance comparison of four commercial human whole-exome capture platforms.四种商用人类全外显子捕获平台的性能比较
Sci Rep. 2015 Aug 3;5:12742. doi: 10.1038/srep12742.
5
The impact of DNA input amount and DNA source on the performance of whole-exome sequencing in cancer epidemiology.DNA输入量和DNA来源对癌症流行病学中全外显子组测序性能的影响。
Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1207-13. doi: 10.1158/1055-9965.EPI-15-0205. Epub 2015 May 19.
6
Comparative clinical sample preparation of DNA and RNA viral nucleic acids for a commercial deep sequencing system (Illumina MiSeq(®)).用于商业深度测序系统(Illumina MiSeq(®))的DNA和RNA病毒核酸的比较临床样本制备
J Virol Methods. 2015 Aug;220:60-3. doi: 10.1016/j.jviromet.2015.04.009. Epub 2015 Apr 19.
7
Solution-based targeted genomic enrichment for precious DNA samples.基于溶液的靶向基因组富集技术用于珍贵 DNA 样本。
BMC Biotechnol. 2012 May 4;12:20. doi: 10.1186/1472-6750-12-20.
8
Choice of plasmid preparation kit influences sequencing results.质粒制备试剂盒的选择会影响测序结果。
Biotechnol Lett. 2010 Mar;32(3):421-2. doi: 10.1007/s10529-009-0157-4. Epub 2009 Nov 7.
9
Exome sequencing from nanogram amounts of starting DNA: comparing three approaches.从纳克量起始DNA进行外显子组测序:三种方法的比较
PLoS One. 2014 Jul 3;9(7):e101154. doi: 10.1371/journal.pone.0101154. eCollection 2014.
10
A capture methyl-seq protocol with improved efficiency and cost-effectiveness using pre-pooling and enzymatic conversion.采用预池化和酶转化提高效率和降低成本的捕获甲基化测序方案。
BMC Res Notes. 2023 Jul 6;16(1):141. doi: 10.1186/s13104-023-06401-3.

引用本文的文献

1
Next‑generation sequencing failure rates in rare tumors: A real‑world single‑institution analysis.罕见肿瘤的下一代测序失败率:一项单机构真实世界分析。
Med Int (Lond). 2025 Mar 18;5(3):27. doi: 10.3892/mi.2025.226. eCollection 2025 May-Jun.
2
Stoichiometric constraints for detection of EV-borne biomarkers in blood.用于检测血液中细胞外囊泡携带生物标志物的化学计量学限制。
J Extracell Vesicles. 2025 Feb;14(2):e70034. doi: 10.1002/jev2.70034.
3
A critical spotlight on the paradigms of FFPE-DNA sequencing.对 FFPE-DNA 测序范式的批判性关注。

本文引用的文献

1
Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective.新一代测序技术的挑战与机遇:细胞病理学家的视角
Cytopathology. 2015 Oct;26(5):271-83. doi: 10.1111/cyt.12265.
2
Performance comparison of four commercial human whole-exome capture platforms.四种商用人类全外显子捕获平台的性能比较
Sci Rep. 2015 Aug 3;5:12742. doi: 10.1038/srep12742.
3
The impact of DNA input amount and DNA source on the performance of whole-exome sequencing in cancer epidemiology.DNA输入量和DNA来源对癌症流行病学中全外显子组测序性能的影响。
Nucleic Acids Res. 2023 Aug 11;51(14):7143-7162. doi: 10.1093/nar/gkad519.
4
Target-enriched long-read sequencing (TELSeq) contextualizes antimicrobial resistance genes in metagenomes.靶向富集长读测序(TELSeq)使宏基因组中的抗生素耐药基因背景化。
Microbiome. 2022 Nov 2;10(1):185. doi: 10.1186/s40168-022-01368-y.
5
mRNA Capture Sequencing and RT-qPCR for the Detection of Pathognomonic, Novel, and Secondary Fusion Transcripts in FFPE Tissue: A Sarcoma Showcase.mRNA 捕获测序和 RT-qPCR 用于检测 FFPE 组织中的标志性、新型和次要融合转录本:肉瘤展示。
Int J Mol Sci. 2022 Sep 20;23(19):11007. doi: 10.3390/ijms231911007.
6
Performance comparison of Agilent new SureSelect All Exon v8 probes with v7 probes for exome sequencing.安捷伦新型 SureSelect All Exon v8 探针与 v7 探针在全外显子测序中的性能比较。
BMC Genomics. 2022 Aug 12;23(1):582. doi: 10.1186/s12864-022-08825-w.
7
Preanalytical Variables and Sample Quality Control for Clinical Variant Analysis.临床变异分析的预分析变量和样本质量控制。
Methods Mol Biol. 2022;2493:331-351. doi: 10.1007/978-1-0716-2293-3_21.
8
System analysis of the sequencing quality of human whole exome samples on BGI NGS platform.基于华大基因测序平台的人类全外显子组测序质量的系统分析。
Sci Rep. 2022 Jan 12;12(1):609. doi: 10.1038/s41598-021-04526-8.
9
A customised target capture sequencing tool for molecular identification of Aloe vera and relatives.一种用于库拉索芦荟及其亲缘种的分子鉴定的定制目标捕获测序工具。
Sci Rep. 2021 Dec 21;11(1):24347. doi: 10.1038/s41598-021-03300-0.
10
Characterization of DNA lesions associated with cell-free DNA by targeted deep sequencing.通过靶向深度测序对游离 DNA 相关的 DNA 损伤进行表征。
BMC Med Genomics. 2021 Jul 28;14(1):192. doi: 10.1186/s12920-021-01040-8.
Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1207-13. doi: 10.1158/1055-9965.EPI-15-0205. Epub 2015 May 19.
4
A new initiative on precision medicine.一项关于精准医学的新倡议。
N Engl J Med. 2015 Feb 26;372(9):793-5. doi: 10.1056/NEJMp1500523. Epub 2015 Jan 30.
5
Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.通过非小细胞肺癌的细针穿刺抽吸活检(FNA)和粗针活检评估表皮生长因子受体(EGFR)和 Kirsten 大鼠肉瘤病毒癌基因(KRAS)的突变状态。
Cancer Cytopathol. 2015 Apr;123(4):230-6. doi: 10.1002/cncy.21513. Epub 2014 Dec 19.
6
Decoding neural transcriptomes and epigenomes via high-throughput sequencing.通过高通量测序解码神经转录组和表观基因组。
Nat Neurosci. 2014 Nov;17(11):1463-75. doi: 10.1038/nn.3814. Epub 2014 Oct 28.
7
Exome sequencing from nanogram amounts of starting DNA: comparing three approaches.从纳克量起始DNA进行外显子组测序:三种方法的比较
PLoS One. 2014 Jul 3;9(7):e101154. doi: 10.1371/journal.pone.0101154. eCollection 2014.
8
Performance comparison of four exome capture systems for deep sequencing.四种外显子捕获系统用于深度测序的性能比较
BMC Genomics. 2014 Jun 9;15(1):449. doi: 10.1186/1471-2164-15-449.
9
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.一种用于定量循环肿瘤DNA的超灵敏方法,具有广泛的患者覆盖范围。
Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. Epub 2014 Apr 6.
10
Liquid biopsies: genotyping circulating tumor DNA.液体活检:循环肿瘤 DNA 的基因分型。
J Clin Oncol. 2014 Feb 20;32(6):579-86. doi: 10.1200/JCO.2012.45.2011. Epub 2014 Jan 21.